Leggett's extensive experience in financial strategy and operations for life science companies, combined with his successful track record in leading IPOs and public offerings, is likely to have a positive impact on Stoke Therapeutics' financial health and its ability to fund ongoing and future projects. His appointment could be seen as a strong strategic fit for Stoke as it transitions to a late-stage clinical company, potentially boosting investor confidence and positively impacting the stock price in the short term.